On behalf of MiECTiS Executive Board we invite you at a MiECS Update Zoom Meeting on Monday 4th November 2024 at 17:00-18:30 CET. The aim of the Meeting is to liaise all centres that implement MiECC in clinical practice with MiECS Steering Committee so
MiECTiS is accepting nominations for the Steering Committee (Vice President, Secretary and Members). These are two-year terms and would begin after MiECTiS Anniversary Meeting, 10-11 May 2024. Please email info@miectis.org with your nomination. Please specify the position, and include a short one or two
MiECS study is new large, high quality RCT under the auspices of MiECTiS, that aims to ultimately address the uncertainty about the effectiveness of MiECC in the light of the resurgence in cardiac activity by most cardiac centres worldwide. By incorporating the
MiECTiS is accepting nominations for the Steering Committee (Vice President, Secretary and Members). These are two-year terms and would begin after 4th Virtual MiECT Symposium, 26th June 2021. Please email info@miectis.org with your nomination. Please specify the position, and include a short
The 4th MiECT Symposium has been DEFERRED due to the ongoing COVID-19 travel and social restrictions currently in place. Therefore, we have now re-scheduled the meeting to be held in Niagara-on-the-Lake, Canada at Prince of Wales hotel, Ontario, London, Ontario, Canada from
Find our first newsletter here Send us your news: info@miectis.org
For more information: https://www.newdelhifaps2020.com/
Read the Supplemental issue of Journal of Thoracic Disease on Minimally Invasive Extracorporeal Circulation: Not a Technique But a Strategy
2019 EACTS/EACTA/EBCP Guidelines on Cardiopulmonary Bypass in Adult Cardiac Surgery. To read the latest EACTS/EACTA/EBCP joint guidelines on cardiopulmonary bypass in adult cardiac surgery please click here. The panel discussion about these guidelines can be found here.
OBJECTIVE: The positive impact of minimally invasive extracorporeal circuits(MiECC) on patient outcome is expected to be most evident in patients with limited physiologic reserves. Nevertheless, most studies have limited their use to low-risk patients undergoing myocardial revascularization. As such, there is little